š”š²šš š¦ššŗšŗš®šæš
ā¢ Motilal Oswal has given a Neutral rating on Zydus LifeSciences with a target price of Rs 660.
ā¢ Zydus LifeSciences delivered a marginal miss on its 2QFY24 financial performance, but the outlook is expected to improve with new launches and R&D efforts.
ā¢ The company is valued at 20x 12M forward earnings, with a focus on innovation and building its ANDA pipeline for sustainable growth.